Solara Active Pharma Q1'27 PAT at ₹163 Mn, Highest in 18 Quarters

Solara Active Pharma Sciences reported strong Q1'27 financial results, with overall revenues up 20% YoY to INR 3,843 Mn and EBITDA up 10% YoY to INR 635 Mn. Profit After Tax (PAT) stood at INR 163 Mn, marking the highest in the last eighteen quarters. The company's Base business (Ex-Ibuprofen) showed robust performance with revenues at INR 3,077 Mn (up 24% YoY) and EBITDA at INR 722 Mn (up 8% YoY), despite input cost pressures. The Ibuprofen business reported revenues of INR 765 Mn with an EBITDA loss of INR 87 Mn. Solara also reduced its net debt by INR 1,346 Mn to INR 4,795 Mn, achieving a Net debt to EBITDA ratio of approximately 1.9.